Niagen Bioscience Inc

Given the decisive break below the 3.61 support with elevated volume and extended EMAs, the downtrend remains intact across all horizons. Long-term and medium-term biases are bearish. Short-term conditions favor execution now. We will sell into the breakdown, leveraging momentum continuation dynamics.

• ↑Q2 revenue reached $29.8 M (+2% YoY), Tru Niagen $24.2 M (+6%).
• ↑E-commerce sales grew 23% YoY to $20.5 M; 10–15% growth guide.
• ↓Stock volatility is extremely high, deterring risk-averse investors.